News | June 23, 2025
Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
FedEx will be displaying a wide-range of effective healthcare packaging and specialized tracking technology
The inspection concluded with no observation (FDA-483) issued.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
